+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics

  • ID: 3970554
  • Report
  • Region: Global
  • 80 Pages
  • La Merie Publishing
1 of 2

This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively.

CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.

Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as:

  • Combination therapies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and Chimeric Antigen Receptor (CAR) T-Cells.

This report describes the profiles of 16 different specific and bispecific anti-CD22 immunotherapeutics based on different treatment modalities. The most advanced molecules has been submitted for regulatory approval. Furthermore, the profiles of nine companies active in the development of anti-CD22 immunotherapeutics are presented.

This report describes and analyzes the:

  • Target Background & Scientific Rationale
  • Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD22 Immunotherapeutics
  • Profiles of Companies with CD22-Targeted Immunotherapeutics.
Note: Product cover images may vary from those shown
2 of 2

1. Target Background & Scientific Rationale

2. Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

3. Competitive Landscape

4. Profiles of Anti-CD22 Immunotherapeutics

  • Naked antibodies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and Chimeric Antigen Receptor (CAR) T-Cells.

5. Profiles of Companies with CD22-Targeted Immunotherapeutics.
References

ADDENDUM: Competitor Analysis of CD22-Targeted Immunotherapeutics

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll